Aficamten: A New Cardiac Myosin Inhibitor for Obstructive Hypertrophic Cardiomyopathy
REDWOOD-HCM was a multicentre, randomised, placebo-controlled, double-blind, dose-finding clinical trial of aficamten in patients with symptomatic oHCM on background medical therapy.